Clinical trials: Dyspareunia (Female)
Dyspareunia, Perineal Tear
Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair
To evaluate the rates of dyspareunia with rapidly absorbing polyglactin 910 compared to poliglecaprone 25 using a validated sexual function questionnaire.
- Conditions
- Dyspareunia, Perineal Tear, Sutured Laceration
- Trial name
- NCT03184077
- Testing
- Laceration Repair with Polyglactin 910, Laceration Repair with poliglecaprone 25
- Where
- United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Dyspareunia
Treating Postmenopausal Dyspareunia Where it Hurts
The purpose of this study is to compare the effectiveness of two low doses of estrogen cream applied to a new location for the treatment of moderate or severe pain during sexual intercourse in postmenopausal women.
- Trial name
- NCT03240081
- Testing
- 50mcg estradiol cream, 100mcg estradiol cream
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Endometriosis
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
- Trial name
- EDELWEISS (NCT02778399)
- Testing
- OBE2109
- Where
- 86 sites in United States, Poland and 2 more
- Volunteers
- 328 people
- Sponsor
- ObsEva SA
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Breast Cancer, Vaginal Dryness
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
It is well documented that women who have breast cancer may experience a decrease in quality of life and sexual functioning due to side effects from adjuvant endocrine therapy, typically aromatase inhibitors (AIs).
- Conditions
- Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
- Trial name
- NCT01697345
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Creighton University
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03986944
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 112 sites in United States, Canada and 1 more
- Volunteers
- 85 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Genitourinary System; Disorder, Female, Burning Vagina
Laser Therapy for Treatment of Urogenital Symptoms in Women
This is a prospective observational study of women undergoing vaginal treatment with the fractional carbon dioxide (fCO2) laser for various urogenital symptoms.
- Conditions
- Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina
- Trial name
- NCT03681678
- Testing
- fCO2 Laser Therapy Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Corewell Health East
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Vaginismus
Botox Injection for Treatment of Vaginismus
The use of Botox injections intravaginally and progressive dilation under anesthesia has been shown to cure vaginismus. This study expands the use of Botox injections to include progressive dilation, post procedure supervised…
- Trial name
- NCT01352546
- Testing
- BOTOX
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Plastic Surgery Professional Association
Sexual Pain Disorders, Postmenopausal Symptoms
Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
This study will evaluate the use of topical 5 or 10% sinecatechins, a botanical drug derived from green tea for the alleviation of sexual pain in the area around the vaginal opening (the vulvar vestibule), that is a main source…
- Conditions
- Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction
- Trial name
- NCT03682601
- Testing
- 5% sinecatechins ointment, 10% sinecatechins ointment
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GTO Pharmaceutical, LLC
Endometriosis
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03992846
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 486 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Vulvovaginal Atrophy, Menopause
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Trial name
- REJOICE (NCT02253173)
- Testing
- Estradiol
- Where
- 105 sites in United States, Canada
- Volunteers
- 764 people
- Sponsor
- TherapeuticsMD
Sexual Dysfunction, Breast Cancer Survivors
Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors
The purpose of this study is to determine whether lactate-containing vaginal lubricant is effective in the treatment of young breast cancer survivors with sexual dysfunction.
- Trial name
- NCT00981305
- Testing
- Lactate-containing vaginal lubricant
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Seoul National University Hospital
Endometriosis
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study…
- Trial name
- NCT02143713
- Testing
- Elagolix
- Volunteers
- 496 people
- Sponsor
- AbbVie
Atrophy of Vagina, Menopause
The Vaginal Health Trial
This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network.
- Conditions
- Atrophy of Vagina, Menopause, Dyspareunia (Female)
- Trial name
- NCT02516202
- Testing
- Vagifem, Replens
- Where
- 2 sites in United States
- Volunteers
- 302 people
- Sponsor
- Fred Hutchinson Cancer Center
Endometriosis
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on…
- Trial name
- NCT03654274
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 169 sites in United States, Argentina and 18 more
- Volunteers
- 802 people
- Sponsor
- Myovant Sciences GmbH
Provoked Vestibulodynia
Integrated Mindfulness-based Cognitive Behaviour Therapy Versus Cognitive Behaviour Therapy for Provoked Vestibulodynia
This randomized trial, nicknamed the COMFORT (Cognitive therapy or Mindfulness FOR Treatment of pvd) study, will compare the effects of an 8-session group Mindfulness-based Cognitive Therapy (MBCT) to an 8-session group Cognitive…
- Trial name
- COMFORT (NCT01704456)
- Testing
- Mindfulness-based Cognitive Therapy, Cognitive Behavioural Therapy
- Where
- 2 sites in Canada
- Volunteers
- 130 people
- Sponsor
- University of British Columbia
Vulvodynia, Vulvodynia, Generalized
Effect of Acupuncture on Patient Vulvodynia Outcomes
This study evaluates acupuncture for the treatment of vulvodynia; specifically if it reduces vulvar pain and pain with intercourse. It also examines how long the effect of acupuncture lasts in women with vulvodynia.
- Conditions
- Vulvodynia, Vulvodynia, Generalized, Vulvar Vestibulitis
- Trial name
- NCT03364127
- Testing
- Active Acupuncture
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Illinois Chicago
Menopause, Vulvovaginal Atrophy
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and…
- Conditions
- Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
- Trial name
- NCT02449902
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- TherapeuticsMD